

1   **Evaluation of production lots of a rapid point-of-care lateral flow  
2 serological test intended for identification of IgM and IgG against the N-  
3 terminal part of the spike protein (S1) of SARS-CoV-2**

4   Tove Hoffman<sup>1</sup>; Linda Kolstad<sup>1</sup>; Bengt Rönnberg<sup>1, 2</sup>; Åke Lundkvist<sup>1</sup>

5   1. Department of Medical Biochemistry and Microbiology, Zoonosis Science Center (ZSC), Uppsala  
6   University, Uppsala, Sweden

7   2. Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden

8

9

10   *Corresponding Author:*

11   Åke Lundkvist, PhD, Prof., [ake.lundkvist@imbim.uu.se](mailto:ake.lundkvist@imbim.uu.se)

12

13   **Key words:** SARS-CoV-2, rapid POC-test, LFIA, lot, IgM, IgG, sensitivity, specificity, PPV,  
14   NPV

15

16

17    **Abstract**

18    **Background and objectives:** Several antibody tests are available to detect SARS-CoV-2  
19    specific antibodies, many of which address different antigens. Rapid point-of-care (POC) tests  
20    have been doubted due to an eventual risk of production errors, although it is unstudied  
21    whether such error would affect test sensitivity and/or specificity. We aimed to evaluate two  
22    separate production lots of a commercially available test intended for rapid detection of IgM  
23    and IgG against the N-terminal part of the SARS-CoV-2 spike protein (S1).

24    **Materials and methods:** Serum samples from individuals with confirmed SARS-CoV-2  
25    infection, by RT-PCR and/or serology, and pre-COVID-19 negative control sera gathered  
26    from a biobank during 2018 were collected. The presence of anti-S1 IgM/IgG was verified by  
27    an in-house Luminex-based serological assay, serving as reference method. The index test  
28    was a commercially available rapid POC-test (the COVID-19 IgG/IgM Rapid Test Cassette  
29    [Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China/Healgen Scientific, LLC,  
30    U.S.A.]).

31    **Results:** One hundred samples were verified positive for anti-S1 IgG (median fluorescence  
32    intensity (MFI)  $\geq 900$ ) and 74 for anti-S1 IgM (MFI  $\geq 700$ ), confirmed by RT-PCR (n=90)  
33    and/or serology (n=89). None of the negative controls (n=200; MFI <300) had SARS-CoV-2  
34    anti-S1 IgM, while one tested positive for SARS-CoV-2 anti-S1 IgG. For the two lots, the  
35    sensitivities of the rapid test were 93.2% (69/74; 95% CI: 85.1% – 97.1%) and 87.8% (65/74;  
36    95% CI: 78.5% – 93.5%) for IgM, respectively 93.0% (93/100; 95% CI: 86.3% – 96.6%) and  
37    100.0% for IgG (100/100; 95% CI: 96.3% – 100.0%). The specificity for both lots was 100%  
38    for IgM (200/200; 95% CI: 98.1% – 100%) and 99.5% for IgG (199/200; 95% CI: 97.2% –  
39    99.9%). The positive predictive value was 100% for IgM and 98.9% and 99.0% for IgG. The  
40    negative predictive value was 95.7% and 97.6% for IgM, and 96.6% and 100.0% for IgG.

41    **Conclusion:** The rapid POC-test used in this study is suitable to assess SARS-CoV-2 anti-S1  
42    specific IgM/IgG, as a measure of previous virus exposure on an individual level. While the  
43    specificity was not affected by production lot, external validation of separate lots of rapid  
44    POC-tests is encouraged to ensure high sensitivity before market introduction.

45

46 **Background**

47 In late 2019, a novel coronavirus causing severe acute respiratory disease was reported from  
48 Wuhan, Hubei Province, China. Within months, the disease COVID-19, caused by the novel  
49 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread to cause a global  
50 pandemic, infecting over 23 million individuals worldwide, as of August 25.<sup>1</sup> Diagnostic  
51 accuracy is vital, as the disease can resemble other viruses and bacteria and cause a wide  
52 range of symptoms; from asymptomatic infections, to those of a mild common cold or more  
53 severe symptoms such as acute respiratory distress syndrome or multi organ failure.<sup>2, 3</sup> The  
54 virus is an enveloped, single-stranded RNA virus of the Coronavirus family. These viruses  
55 share structural similarities and are composed of 16 non-structural proteins and four structural  
56 proteins: the spike (S), envelope, membrane, and nucleocapsid (N) proteins. In turn, the N-  
57 terminal part of the S protein (S1) contains a receptor-binding domain (RBD) that specifically  
58 recognizes the angiotensin-converting enzyme 2 (ACE2) receptor in humans, which SARS-  
59 CoV-2 has been identified to bind to in order to infect the human host.<sup>4-6</sup>

60 There is convincing evidence that a majority of patients with past COVID-19  
61 develop neutralizing antibodies against the virus.<sup>7</sup> For detection of antibodies, there are  
62 several available serological assays developed to identify individuals with recent and past  
63 exposure and to assess the extent of exposure in a population. In turn, this might help to  
64 decide on application, enforcement or relaxation of containment measures. As proper  
65 neutralization tests are cumbersome, time-consuming and require biosafety level 3  
66 laboratories, there are several available tests that address different SARS-CoV-2 specific  
67 antigens, the most common being the N-protein or the S-protein.

68 In a recent population-based study from Spain, different seroprevalences were  
69 estimated by a chemiluminescent microparticle immunoassay (CMIA) for detection of anti-N  
70 IgG, and a lateral flow immunochromatographic assay (LFIA) for detection of anti-S1 IgG.<sup>3</sup>  
71 Whether the difference in estimated seroprevalence could be explained by dynamic  
72 appearance of antibodies targeting the different viral proteins or whether the rapid point-of-  
73 care (POC) test did not have as good performance as the CMIA-test, is unknown.

74 Available serological methods to date either rely on quantitative laboratory-  
75 based assays or on qualitative LFIA's. While the lateral flow tests have the advantage of being  
76 a POC-analysis where results can be given directly to the patient within minutes from sample  
77 collection, rapid POC-tests have been attributed a potential risk of production errors that may  
78 result in unreliable performance of the test. There is, however, to our knowledge no study  
79 published to date investigating whether the sensitivity and/or specificity varies between

80 production lots of a rapid test. In this study, we therefore aimed to evaluate two separate  
81 production lots of one commercially available rapid POC-test (the COVID-19 IgG/IgM Rapid  
82 Test Cassette [Zhejiang Orient Gene Biotech Co Ltd, Huzhou, Zhejiang, China]) and its  
83 accuracy in identifying anti-S1 IgM/IgG. As reference standard, presence of SARS-CoV-2  
84 S1-specific IgM and IgG in positive controls were verified with an in-house Luminex-based  
85 COVID-19 assay (Magpix technology, Luminex Corporation).

86

87

## 88 **Material and methods**

### 89 *Serum samples*

90 Positive controls constituted of serum from Swedish COVID-19 patients or convalescents,  
91 confirmed positive for SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-  
92 PCR) and/or serology for SARS-CoV-2 specific IgM and IgG, between March to July 2020.  
93 Negative controls constituted of serum from babies (6-12 months old) and randomly selected  
94 blood donor sera from the Uppsala Academic Hospital from individuals, without any known  
95 history of SARS-CoV-2 infection/COVID-19 and before the COVID-19 pandemic (i.e.  
96 collected 2018). Clinical samples that had been deposited in Uppsala Biobank were  
97 anonymized and used in accordance with local ethical guidelines. They were all used with  
98 informed consent according to the Swedish Biobank law, which allows anonymized  
99 diagnostic patient samples to be used for purposes similar to those of the original sampling.  
100 The study was approved by the Swedish Ethical Review Authority (2020–02047).

101

### 102 *Reference method*

103 Samples were pre-specified when evaluating the index test. The reference method used was a  
104 Luminex-based (Magpix technology, Luminex Corporation) SARS-CoV-2-specific assay,  
105 developed in-house and used due to high specificity and sensitivity in detecting SARS-CoV-2  
106 S1-specific IgM and IgG (manuscript in preparation). Samples with confirmed SARS-CoV-2  
107 infection that tested positive for SARS-CoV-2 S1-specific IgG with a median fluorescence  
108 intensity (MFI)  $\geq 900$  were used as reference for positive IgG-samples. Of those, samples  
109 positive for SARS-CoV-2 S1-specific IgM with an MFI  $\geq 700$  served as reference for positive  
110 IgM-samples. Samples with an MFI  $< 300$  were considered negative for anti-S1 IgM and IgG.  
111 All samples were from unique individuals and analysed anonymously.

112

113

114 *Index test*

115 The index test (rapid POC-test) used was run according to the manufacturer's instructions  
116 (COVID-19 IgG/IgM Rapid Test Cassette; Product/Model: GCCOV-402a, Lot no. 2003287  
117 [Lot A] and Lot no. 2004156 [Lot B]; Zhejiang Orient Gene Biotech Co Ltd, Huzhou,  
118 Zhejiang, China / Healgen Scientific LLC, Houston, USA). This test targets anti-S1 IgM and  
119 IgG. Briefly, 5 µl of serum were added to the test slide, followed by 80 µl of the buffer  
120 provided in the kit. The results were read after 10 minutes (max 15 min) by the naked eye.  
121 Test results were blinded to the assessors of the index test, as well as to the assessors of the  
122 reference standard.

123

124 *Analysis*

125 Only index tests in which the control line changed colour were regarded as valid (no test was  
126 excluded from analysis). If a line was observed for IgM and/or IgG, the test was considered  
127 positive. The intensity of the colour was not judged. Sample sizes were determined in order to  
128 comply with the recommendations from the Swedish Public Health Agency for validation of  
129 COVID-19 related serological assays. The sensitivity of the index test was calculated as the  
130 proportion of index positives among reference positives, and specificity as the proportion of  
131 index negatives among reference negatives. The Wilson Score method was used to calculate  
132 95% confidence intervals (95% CI). Analyses were performed with STATA v13.1 (StataCorp,  
133 Texas, USA). Plots for positive and negative predictive value (PPV; NPV) as a function of  
134 prevalence were created in R v4.0.0 (R Core Team, 2020). Reporting of results are made  
135 according to the 2015 Standards for Reporting Diagnostic Accuracy (STARD) statement.<sup>8</sup>

136

137

138 **Results**

139 *Selected serum samples*

140 One hundred serum samples, confirmed by RT-PCR (n=90) and/or by serology (n=89), had  
141 an MFI  $\geq 900$  (range: 998 – 6,477) for anti-S1 IgG. Of those, 74 had an MFI  $\geq 700$  (range: 738  
142 – 5,916) for anti-S1 IgM. None of the 200 samples from 2018 gathered from the biobank  
143 tested positive for anti-S1 IgM and IgG (MFI <300). A flow diagram of sampling is depicted  
144 in Figure 1.

145

146

147

148 *Index test*

149 With the index test, none of the 200 negative sera from blood donors and babies tested IgM  
150 positive (0/200, 0% [95% CI: 0.0-1.9%]), while one tested IgG positive (1/200, 0.5 %, [95%  
151 CI: 0.1-2.8%]). This was the case in both production lots tested (Tables 1 and 2). The single  
152 IgG-positive sample was re-analysed and remained IgG positive in the second test in both  
153 lots. Of the 74 IgM-positive samples, five tested IgM negative (6.8% [95% CI: 2.9-14.9%]) in  
154 Lot A and nine (12.2% [95% CI: 6.5-21.5%]) in Lot B. Of the 100 IgG-positive samples,  
155 seven tested IgG negative (7.0% [95% CI: 3.4-13.7%]) in Lot A while none tested IgG  
156 negative in Lot B (0% [95% CI: 0.0% to 3.7%]). The MFI of the false IgG negatives in Lot A  
157 ranged between 998 - 3,453. The MFI of the false IgM negatives ranged 761 - 1,340 and 738 -  
158 1,641 for Lot A and B, respectively.

159

160 *Sensitivity, specificity and predictive values*

161 Based on the results described above and summarized in Tables 1 and 2, the index test had a  
162 sensitivity of 87.8% and 93.2% for IgM and 93.0% and 100.0% for IgG (Table 3). The test  
163 exhibited an overall specificity of 100.0% for IgM and 99.5% for IgG. The PPV (probability  
164 of have been infected and having antibodies given a positive test result) was 100% for IgM  
165 and 98.9% and 99.0% for IgG. The NPV (probability of not yet been infected and not having  
166 antibodies given a negative test result) was 95.7% and 97.6% for IgM, and 96.6% and 100.0%  
167 for IgG. For both antibody types, PPV and NPV remained high over a broad range of  
168 prevalence (Figure 2).

169

170

171 **Discussion**

172 In this study, we evaluated different production lots of a commercially available rapid POC-  
173 test for detection of IgM and IgG against the S1-protein of SARS-CoV-2. The test displayed a  
174 high sensitivity and specificity when compared against a Luminex-based (Magpix  
175 technology) SARS-CoV-2-specific assay. Comparing two different production lots, the  
176 sensitivity was 87.8% and 93.2% for IgM and 93.0% and 100.0% for IgG. Regarding the  
177 specificity, it remained at 100.0% and 99.5% for IgM and IgG, respectively. A high  
178 performance of the rapid test has also been reported elsewhere, with a specificity ranging  
179 from 97.5% to 100% for IgG and 100% for IgM, and a sensitivity ranging from 96.7% to 98%  
180 for IgG and 68% to 100% for IgM.<sup>10</sup> The Swedish Public Health Agency has warranted a IgG  
181 specificity of  $\geq 99.5\%$  and a sensitivity of  $\geq 90\%$  for COVID-19 related serological assays to

182 be recommended as an assay for assessment of antibody presence on an individual level.<sup>11</sup> In  
183 this study, both investigated production lots of the investigated POC-test reached that  
184 standard and may, thus, be suitable for antibody screening in Sweden.

185 Differences in sensitivity of the two production lots in the current study might  
186 be explained by small differences in the amount of antigen added during production of the  
187 rapid test, which could lead to a weaker qualitative response and, thus, effecting the  
188 sensitivity of the test. Different amounts, and not varying quality, of the antigen would also  
189 explain why the test was still highly specific in both lots. Previously, we have reported a  
190 sensitivity of 69% (20/29) and 93% (27/29) for IgM and IgG respectively for the same rapid  
191 POC-test.<sup>12</sup> In that study, positive controls constituted of serum from PCR-confirmed  
192 COVID-19 patients or convalescents with unknown serological response.<sup>12</sup> Thus, some of the  
193 samples serving as positive controls could have been collected in the seronegative window or  
194 lost the antibodies, explaining the higher sensitivity observed in the current study.

195 In a recent population-based study from Spain; more than 51,000 individuals  
196 were tested by a CMIA for detection of anti-N IgG and the same rapid POC-test as  
197 investigated in the current study, which targets anti-S1 IgM/IgG.<sup>3</sup> Comparing the two tests,  
198 the authors observed different seroprevalences of SARS-CoV-2 specific IgG. Given the high  
199 performance in detection of anti-S1 IgM and IgG observed in the current study, a possible  
200 explanation for the discrepancy could be that the median seroconversion time, and the  
201 antibody peak time, have been observed to occur later for anti-S1 IgM/IgG, as compared to  
202 anti-N IgM/IgG.<sup>13,14</sup> Moreover, anti-S1 IgG levels have been observed to be four times higher  
203 during convalescence than in the acute phase in about 40% of patients,<sup>14</sup> while measurement  
204 of only anti-N IgM/IgG have been observed to substantially underestimate the proportion of  
205 SARS-CoV-2 infections in general.<sup>15</sup> Thus, an inter-individual heterogeneity in antigens to  
206 which different patients develop antibodies against, or the heterogenous dynamics of antibody  
207 appearance, could be a possible explanation to the cumbersome process of inventing a single  
208 test that can identify past exposure to the virus with as close to 100% accuracy as possible,  
209 despite the worlds weighted efforts. As the current study only aimed to evaluate the  
210 performance of the rapid POC-test in detecting anti-S1 IgM/IgG, the non-population-based  
211 and predefined study design inherits a weakness in the sense that the POC-test investigated  
212 does not detect individuals with antibodies against the N- or other parts of the S-protein. Due  
213 to the inter-individual differences in dynamics of these antibody subtypes, it has been  
214 suggested that a combination of antibody tests, targeting different viral proteins, may be the  
215 best strategy in order to increase sensitivity and/or specificity when screening for SARS-CoV-

216 2 specific antibodies.<sup>3</sup> However, as anti-S antibodies can block the ACE2-receptor and thus  
217 prevent SARS-CoV-2 from infecting the human host,<sup>13</sup> a positive result from the studied rapid  
218 POC-test could indicate immunity against re-infection as long as adequate titers are upheld.

219 To the best of our knowledge, this is the first study to evaluate the impact of  
220 production lots on the performance of a rapid POC-test intended for detection of SARS-CoV-  
221 2 specific anti-S1 IgM and IgG. The world is looking for serological assays that can help to  
222 decide on relaxation of containment measures and POC-tests are optimal for such purpose  
223 given the lower associated costs, easier implementation, and the potentially increased uptake  
224 as compared with laboratory-based assays. The fact that the PPV and NPV for IgG remained  
225 high over a broad range of prevalence indicates that the investigated rapid POC-test is suitable  
226 for screening of SARS-CoV-2 specific IgG antibodies in regions with varying prevalence and  
227 during different stages of the pandemic, and therefore could aid in determining containment  
228 measures. The observed differences in sensitivity between the two production lots highlight  
229 the need for external validation of each production lot before a rapid POC-test is made  
230 available on the market.

231

232

### 233 **Acknowledgements**

234 This work was supported by the Swedish Research Council (VR, 2017-05807 and 2018-  
235 02569). The rapid tests that have enabled this study were donated by the Swedish company  
236 Noviral AB (organization number: 559175-7942).

237

238

239

### 240 **Disclosure statement**

241 The authors declare no conflicts of interest.

242

243

### 244 **References**

- 245 1. Worldometer. Worldometer, Coronavirus. 2020.
- 246 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu  
247 P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I

- 248 and Research T. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N  
249 Engl J Med.* 2020;382:727-733.
- 250 3. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M,  
251 Sanmartin JL, Fernandez-Garcia A, Cruz I, Fernandez de Larrea N, Molina M,  
252 Rodriguez-Cabrera F, Martin M, Merino-Amador P, Leon Paniagua J, Munoz-Montalvo  
253 JF, Blanco F, Yotti R and Group E-CS. Prevalence of SARS-CoV-2 in Spain (ENE-  
254 COVID): a nationwide, population-based seroepidemiological study. *Lancet.* 2020.
- 255 4. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT and Veesler D. Structure,  
256 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.*  
257 2020;181:281-292 e6.
- 258 5. Wan Y, Shang J, Graham R, Baric RS and Li F. Receptor Recognition by the Novel  
259 Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of  
260 SARS Coronavirus. *J Virol.* 2020;94.
- 261 6. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A and Li F.  
262 Structural basis of receptor recognition by SARS-CoV-2. *Nature.* 2020;581:221-224.
- 263 7. Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics  
264 with neutralizing antibody levels in patients who have recovered from mild COVID-19  
265 in Shanghai, China. *JAMA Intern Med.* Published online August 18, 2020.  
266 doi:[10.1001/jamainternmed.2020.4616](https://doi.org/10.1001/jamainternmed.2020.4616)
- 267 8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG,  
268 Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L,  
269 Korevaar DA, Cohen JF and Group S. STARD 2015: an updated list of essential items  
270 for reporting diagnostic accuracy studies. *BMJ.* 2015;351:h5527.
- 271 9. Research NsFNLfC. Serology Test Evaluation Report for “COVID-19 IgG/IgM Rapid  
272 Test Cassette” from Healgen.
- 273 10. Tollånes M, Abildsnes E, Baevre-Jensen R, Kierkegaard H, Jenum PA, Breivik A and  
274 Sandberg S. Report 2: Evaluation of 17 rapid tests for detection of antibodies against  
275 SARS-CoV-2. 2020.
- 276 11. Folkhälsomyndigheten. Vägledning för antikroppspåvisning, version 3. *Vägledning för  
277 antikroppspåvisning.* 2020;3.
- 278 12. Hoffman T, Nissen K, Krambrich J, Rönnberg B, Akaberi D, Esmailzadeh M, Salaneck  
279 E, Lindahl J and Lundkvist Å. Evaluation of a COVID-19 IgM and IgG rapid test; an  
280 efficient tool for 4 assessment of past exposure to SARS-CoV-2. *Infection Ecology &  
281 Epidemiology.* 2020.

- 282 13. Grandjean L, Saso A, Ortiz A, Lam T, Hatcher J, Thistlethwaite R, Harris M, Best T,  
283 Johnson M, Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K  
284 and Goldblatt D. Humoral Response Dynamics Following Infection with SARS-CoV-2.  
285 *medRxiv*. 2020:2020.07.16.20155663.
- 286 14. Huang J, Mao T, Li S, Wu L, Xu X, Li H, xu C, Su F, Dai J, Shi J, Cai J, Huang C, Lin  
287 X, Chen D, Lin X, Sun B and Tang S. Long period dynamics of viral load and  
288 antibodies for SARS-CoV-2 infection: an observational cohort study. *medRxiv*.  
289 2020:2020.04.22.20071258.
- 290 15. Fenwick C, Croxatto A, Coste AT, Pojer F, Andre C, Pellaton C, Farina A, Campos J,  
291 Hacker D, Lau K, Bosch BJ, Gonseth Nussle S, Bochud M, D'Acremont Genton V,  
292 Trono D, Greub G and Pantaleo G. Changes in SARS-CoV-2 Antibody Responses  
293 Impact the Estimates of Infections in Population-Based Seroprevalence Studies.  
294 *medRxiv*. 2020:2020.07.14.20153536.

295

296 **TABLES**

297

298 **Table 1.** Results for serum samples with SARS-CoV-2 specific anti-receptor binding domain of spike protein  
299 IgM, confirmed with Luminex technology, and pre-COVID-19 negative controls for two production lots of a  
300 rapid point-of-care test.

Index test

Reference method	Lot A			Lot B		
	IgM*		Total	IgM		Total
	Positive	Negative		Positive	Negative	
IgM Positive	69	5	74	65	9	74
IgM Negative	0	200	200	0	200	200
Total	69	205	274	65	209	274

301 \*Immunoglobulin M

302

303

304 **Table 2.** Results for serum samples with SARS-CoV-2 specific anti-receptor binding domain of spike protein  
305 IgG, confirmed by Luminex technology, and pre-COVID-19 negative controls for two production lots of a rapid  
306 point-of-care test.

Index test

Reference method	Lot A			Lot B		
	IgG*		Total	IgG		Total
	Positive	Negative		Positive	Negative	
IgG Positive	93	7	100	100	0	100
IgG Negative	1	199	200	1	199	200
Total	94	206	300	101	199	300

307 \*Immunoglobulin G

308

309

310

311   **Table 3.** Performance of two production lots of a rapid IgM/IgG test cassette, evaluated using reference samples  
312 confirmed by Luminex technology.


	Index test performance			
	IgM		IgG	
	n	% (95% CI)	n	% (95% CI)
<b>Lot A</b>				
Sensitivity	69/74	93.2 (85.1 – 97.1)	93/100	93.0 (86.3 – 96.6)
Specificity	200/200	100.0 (98.1 – 100.0)	199/200	99.5 (97.2 – 99.9)
PPV	69/69	100.0 (94.7 – 100.0)	93/94	98.9 (94.2 – 99.8)
NPV	200/205	97.6 (94.4 – 99.0)	199/206	96.6 (93.2 – 98.3)
<b>Lot B</b>				
Sensitivity	65/74	87.8 (78.5 – 93.5)	100/100	100.0 (96.3 – 100.0)
Specificity	200/200	100.0 (98.1 – 100.0)	199/200	99.5 (97.2 – 99.9)
PPV	65/65	100.0 (94.4 – 100.0)	100/101	99.0 (94.6 – 99.8)
NPV	200/209	95.7 (92.0 – 97.7)	199/199	100.0 (98.1 – 100.0)

313   The Wilson Score method was used to calculate confidence intervals for proportions. CI indicates confidence  
314 interval; IgG, immunoglobulin G; IgM, immunoglobulin M; PPV, positive predictive value; NPV, negative  
315 predictive value.

316

317 **FIGURES**


318



319

320 **Figure 1.** Flow diagram of sampling.

321



322

323 **Figure 2.** Positive and negative predictive values (PPV; NPV) for two production lots of a rapid point-of-care  
324 test as a function of prevalence. Dotted red line indicates study prevalence (33%; 100/300).

325